Clinical trials: Endocrine System Disorder
Type 2 Diabetes Mellitus
Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
The study objective is to demonstrate the superiority and safety of the combination therapy (as a fix-dose combination) with Gemigliptin and Glimepiride, compared to the Glimepiride monotherapy in patients with type 2 diabetes.
- Trial name
- NCT02089126
- Testing
- Gemigliptin/Glimepiride combination
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- LG Life Sciences
Secondary Hyperparathyroidism
Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation
Eighty-six eligible participants with secondary hyperparathyroidism will be enrolled at thirteen sites in Russia. Planned therapy will be six months.
- Trial name
- NCT01401478
- Where
- 13 sites in Russia
- Volunteers
- 86 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Multiple Electrode Aggregometry & Clopidogrel Resistance
Antiplatelet therapy with aspirin-clopidogrel reduces the risk of cardiovascular episodes after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD), Myocardial Infraction
- Trial name
- NCT01991093
- Where
- 3 sites in Greece
- Volunteers
- 280 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Advanced Solid Tumors, Ovarian Cancer
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT02367352
- Testing
- Alisertib, Paclitaxel
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 9 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Type 2 Diabetes
Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2 diabetes who have inadequate blood glucose…
- Trial name
- NCT06290349
- Testing
- DA5221-T1, DA5221-T2, DA5221-B1
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Dong-A ST Co., Ltd.
Type 2 Diabetes Mellitus
A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.
- Trial name
- NCT03736785
- Testing
- LY3209590, Insulin Degludec
- Where
- 44 sites in United States, Mexico and 1 more
- Volunteers
- 399 people
- Sponsor
- Eli Lilly and Company
Diabetes
One Touch® Verio®IQ European Clinical Outcomes Study
Evaluation of the clinical benefits of One Touch VerioIQ system.
- Trial name
- NCT01631643
- Testing
- One Touch VerioIQ Blood Glucose Monitor
- Sponsor
- LifeScan
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial…
- Trial name
- EB-DUALNK-OV (NCT07589543)
- Testing
- EB-DUALNK, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
The purpose of this study is to assess safety and efficacy of empagliflozin compared to sitagliptin in patients with type 2 diabetes mellitus who are treatment-naive or on treatment with metformin and have insufficient glycaemic…
- Trial name
- NCT01984606
- Testing
- Empagliflozin, Sitagliptin
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably > 1500 mg metformin in patients with…
- Trial name
- NCT00622284
- Testing
- BI 1356, Glimepiride
- Where
- 221 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,560 people
- Sponsor
- Boehringer Ingelheim
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Diabetes
Evaluation of an Ascensia Lancing System
The purpose of this study was to determine if untrained subjects with diabetes could perform basic tasks with the Styx lancing device to obtain adequate blood volume from fingerstick and palm lancings for Blood Glucose Meter…
- Trial name
- NCT02606838
- Testing
- Styx Lancing Device
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Ascensia Diabetes Care
Diabetes Mellitus
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.
- Trial name
- NCT00701935
- Testing
- exenatide
- Where
- 17 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Diabetes Mellitus
A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects
Primary Objective: To evaluate the effect of food on the single-dose pharmacokinetics of sotagliflozin relative to a fasted state in healthy adult male and female subjects.
- Trial name
- NCT03174548
- Testing
- Sotagliflozin (SAR439954)
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Foot Ulcers
Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers
This study is to evaluate the efficacy of OCM™ used in combination with off-loading devices for the treatment of diabetic foot ulcers.
- Trial name
- NCT05417425
- Testing
- Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Omeza, LLC
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Ovarian Cancer
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.
- Trial name
- NCT00345540
- Testing
- NOV-002, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cellectar Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.